BioLine RX Shares Outstanding vs. Current Ratio

BLRX Stock  ILS 7.00  0.10  1.41%   
Based on the key profitability measurements obtained from BioLine RX's financial statements, BioLine RX may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess BioLine RX's ability to earn profits and add value for shareholders.
For BioLine RX profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLine RX to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLine RX utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLine RX's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLine RX over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between BioLine RX's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLine RX is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLine RX's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

BioLine RX Current Ratio vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining BioLine RX's current stock value. Our valuation model uses many indicators to compare BioLine RX value to that of its competitors to determine the firm's financial worth.
BioLine RX is number one stock in shares outstanding category among its peers. It also is number one stock in current ratio category among its peers . The ratio of Shares Outstanding to Current Ratio for BioLine RX is about  180,247,462 . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLine RX by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLine RX's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

BioLine Current Ratio vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

BioLine RX

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
922.87 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

BioLine RX

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
5.12 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

BioLine Current Ratio Comparison

BioLine RX is currently under evaluation in current ratio category among its peers.

BioLine RX Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in BioLine RX, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLine RX will eventually generate negative long term returns. The profitability progress is the general direction of BioLine RX's change in net profit over the period of time. It can combine multiple indicators of BioLine RX, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.

BioLine Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on BioLine RX. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLine RX position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLine RX's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in BioLine RX without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Correlations Now

   

Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Use Investing Themes to Complement your BioLine RX position

In addition to having BioLine RX in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate Thematic Idea Now

Real Estate
Real Estate Theme
Publicly traded companies that are involved in real estate development, property maintenance and management of real estate investment trusts (REIT) funds. The Real Estate theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in BioLine Stock

To fully project BioLine RX's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioLine RX at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioLine RX's income statement, its balance sheet, and the statement of cash flows.
Potential BioLine RX investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although BioLine RX investors may work on each financial statement separately, they are all related. The changes in BioLine RX's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioLine RX's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.